Novo Nordisk shares fell as much as 10% after new data showed its next-generation weight loss candidate CagriSema failed to match Eli Lilly’s tirzepatide in a head-to-head obesity study. The open-label REDEFINE 4 trial delivered 23% average weight loss for CagriSema, short of the study’s primary goal of demonstrating non-inferiority to tirzepatide, which hit 25.5%. The miss undercuts the bull case that Novo could follow Wegovy’s surge with a best-in-class successor and reignites questions about the company’s pipeline momentum in a market where perfection is priced in.
Market reaction – Shares of Novo Nordisk A S, the dominant force in GLP-1 obesity drugs, sold off sharply in Copenhagen, erasing tens of billions in market value as investors recalibrated growth assumptions beyond semaglutide. U.S. ADRs of Novo Nordisk, which trade under ticker NVO, tracked the decline. Pressure intensified on a high multiple that bakes in sustained leadership in obesity and diabetes. This is not the first snap lower tied to CagriSema. The stock underperformed in March 2025 after another study, REDEFINE 2, posted lower-than-hoped weight loss. With 10% off in a single session, traders are repositioning around the gap between Novo’s current franchise strength and emerging competitive realities.
Head-to-head loss – The REDEFINE 4 result matters because it is clean, direct competition. CagriSema, a once-weekly combination of cagrilintide and semaglutide, went up against tirzepatide in people with obesity. At 23% weight loss, it missed the trial’s primary endpoint of showing it was not inferior to Lilly’s 25.5% outcome. In obesity medicines, small percentage gaps are not trivial. They can influence prescriber choices, payer negotiations, and long-run share. The study was open-label, which can introduce behavior effects, but the headline is what screens light up on: CagriSema did not meet its bar against tirzepatide. That dulls Novo’s narrative that it can outflank Lilly at the top of the efficacy pyramid.
Expectations reset – This comes on the heels of a pattern that has been chipping at the CagriSema story. In prior testing, notably REDEFINE 2, the combination posted 15.7% weight loss, below the company’s ambition of about 25%. Investors largely tolerated that softness given the complexity of trial designs and patient mixes and the belief the head-to-head would vindicate the drug. It did not. The cumulative effect is clear: Street models that embedded a premium ramp for CagriSema will have to come down. That affects medium-term revenue and margin trajectories because Novo had framed CagriSema as a pillar beyond Wegovy and Ozempic. Without clear non-inferiority, let alone superiority, the franchise extension case weakens and the probability-weighted value of the asset slides.
Street verdict – The sell-side is moving to reflect the miss. Morgan Stanley trimmed its price target to 42 from 43 and kept an Underweight rating, highlighting a neutral sector setup and comparatively better earnings growth elsewhere in Europe. Expect more estimate cuts as analysts bake in lower peak share and slower uptake for CagriSema. Volatility around GLP-1 leaders tends to be violent because of how concentrated index-level performance has become in a few mega-cap names. As guidance seasons roll on, watch for whether management leans into cost discipline, capital returns, or alternative pipeline assets to backfill the delta. The message from the tape is blunt: the market was paying for a cleaner handoff to the next wave. It did not get it.
Lilly advantage – The immediate winner is Eli Lilly, whose tirzepatide has been setting the pace with Zepbound in obesity and Mounjaro in diabetes. Beating CagriSema on weight loss in a direct comparison reinforces Lilly’s edge and complicates Novo’s efforts to reset the narrative before more late-stage readouts hit. In a category driven by efficacy, tolerability, and access, each head-to-head datapoint shapes the pecking order. Weekly dosing is no longer a differentiator. If patients and providers perceive even a 2 to 3 percentage point advantage in average weight loss, inertia tilts to Lilly unless Novo can show offsets like better side effect profiles, durability, cardiometabolic benefits, or easier access. Today’s data give Lilly more leverage with prescribers and payers.
Pricing and access – Payers are fixing on comparative outcomes to guide formularies and prior authorizations. A non-inferiority miss can be the difference between preferred and parity positioning, rebate depth, or step therapy requirements. Novo’s existing blockbusters, Wegovy and Ozempic, still throw off immense cash flow and address a vast unmet need. But the investment case for a sustained premium multiple relied on new assets keeping Novo either at par or ahead versus Lilly on efficacy. That calculus gets tougher if CagriSema is seen as second best. Pricing power narrows, while marketing and access costs rise to maintain share, crimping operating leverage. For a company at Novo’s scale, even small changes in assumptions on net price or share can swing billions in enterprise value.
Risk profile and pipeline – The company has weathered supply constraints, capacity expansions, and policy noise. The bigger swing factor now is pipeline quality versus peers. Without the CagriSema kicker, investors will focus more on what else can deliver. Any readthroughs from open-label to blinded trials, subgroup analyses on discontinuation rates, nausea and GI tolerability, or metabolic and cardiovascular endpoints will matter. Novo has leaned on best-in-class execution to compensate when topline efficacy is not the headline winner. That strategy still counts, but it gets marked to market after a clean loss to tirzepatide. Meanwhile, a 10% drawdown exposes how much perfection was embedded. Momentum names do not get much room for B-plus outcomes when an A exists across the street.
What to watch next – Three checkpoints will decide if this selloff sticks or fades. First, additional CagriSema data that could reframe the asset beyond raw weight loss, including durability and comorbidity outcomes. Second, management’s capital allocation and messaging, especially whether it tempers volume and margin guidance tied to next-wave obesity drugs, or signals faster returns of cash to shareholders to stabilize the base. Third, competitive signals from Lilly on manufacturing, launches, and new mechanisms that could widen the efficacy gap. If Novo can prove better tolerability or adherence, some share can be defended even without non-inferiority. If not, payer panels and KOLs will move to the higher-efficacy option. In a market that rewards clear winners, incrementalism does not clear the bar.
The bottom line – Novo Nordisk remains the franchise leader in GLP-1s, but leadership was already priced into the stock. CagriSema missing non-inferiority to tirzepatide at 23% weight loss cracks the next-leg-up story and shifts bargaining power to Lilly. The Street will cut back peak sales and margin optimism for Novo’s pipeline while waiting for more data to argue for durability or safety advantages. In the interim, the multiple compresses, execution risk rises, and the market re-learns that in obesity drugs, two points of efficacy can move 10% of market cap.
